Side-by-side financials for BTAI and LLY. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BTAI | LLY |
|---|---|---|
| Market cap | - | $1.072 T |
| US-listed rank | - | #11 |
| Revenue (latest FY) | $642.00K | $65.18B |
| Net income (latest FY) | -$69.90M | $20.64B |
| Net margin | -10887.4% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 656 | 989 |
In their latest fiscal years, BioXcel Therapeutics, Inc. reported $642.00K in revenue while ELI LILLY & Co reported $65.18B.
Full pages: BioXcel Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.